Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3 on the page, indicating a software deployment update.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2 on the page. This minor version update does not change any study information or user-facing content.SummaryDifference0.1%

- Check33 days agoChange DetectedInvestigator attribution was split into a standalone name entry and new metadata lines (Last verified, Last known status). The page also introduces new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a standardized label for Intervention/Treatment.SummaryDifference2%

- Check40 days agoChange DetectedA new revision tag labeled Revision: v3.5.5 appears, replacing the prior Revision: v3.5.4.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page now displays Revision: v3.5.4, updating the revision label from the previous v3.5.3. This reflects a new entry in the page's revision history.SummaryDifference0.1%

- Check76 days agoChange DetectedThe interface revision tag was updated from v3.5.2 to v3.5.3. This reflects a minor platform update with no changes to the study details presented on the page.SummaryDifference0.1%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.